

Review

Depletion and Supplementation of Coenzyme Q10 in Secondary Deficiency Disorders

David Mantle^{1,†}, Nadia Turton^{2,†}, Iain P. Hargreaves^{2,*,†}

¹Pharma Nord (UK) Ltd, NE61 2DB Morpeth, UK

²School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, L3 3AF Liverpool, UK

*Correspondence: i.hargreaves@ucl.ac.uk (Iain P. Hargreaves)

†These authors contributed equally.

Academic Editor: Graham Pawelec

Submitted: 16 July 2022 Revised: 5 November 2022 Accepted: 2 December 2022 Published: 19 December 2022

Abstract

Coenzyme Q10 (CoQ10) deficiency is broadly divided into two types, primary and secondary. Primary CoQ10 deficiencies are relatively rare disorders resulting from mutations in genes directly involved in the CoQ10 biosynthetic pathway, and are not a subject of this article. Secondary CoQ10 disorders are relatively common, and may occur for a variety of reasons; these include mutations in genes not directly related to the synthetic pathway, oxidative stress induced reduction of CoQ10, and the effects of pharmacological agents such as statins. CoQ10 is of key importance in cell metabolism; in addition to its role in mitochondrial oxidative phosphorylation, it is a major endogenous antioxidant, and has a role in the metabolism of sulphides, lipids and amino acids. Given its importance in cell metabolism, it is unsurprising that secondary CoQ10 deficiency has been linked with a wide range of disorders. In this article, we have reviewed evidence of secondary CoQ10 deficiency in both common and less common disorders, and highlighted those disorders in which CoQ10 supplementation has been shown to be of significant clinical benefit.

Keywords: coenzyme Q10; ubiquinone; secondary deficiency; heart failure; kidney disease; diabetes; liver disease; neurological disorders; pulmonary disorders; periodontal disease

1. Introduction

Coenzyme Q10 (CoQ10) is usually described as a vitamin-like substance, although it is endogenously synthesised within most cell types. CoQ10 has a number of functions of vital importance to normal cell function; these include (i) its key role in cellular energy supply/ATP synthesis via mitochondrial oxidative phosphorylation; (ii) its role as a major endogenously synthesised lipid soluble antioxidant, protecting cellular/subcellular organelle membranes from free radical induced oxidative damage; (iii) its role in the metabolism of lysosomes, sulphides, amino acids and cholesterol; (iv) its role as an anti-inflammatory agent [1,2]. Because of the multiplicity of roles in cell function, it is not surprising that deficiency of CoQ10 has been implicated in the pathogenesis of a wide range of disorders. CoQ10 deficiency is broadly divided into primary and secondary types [3]. Primary CoQ10 deficiency results from mutations in genes involved in the CoQ10 biosynthetic pathway. At least 10 genes are required for the biosynthesis of functional CoQ10, a mutation in any one of which can result in a deficit in CoQ10 status. Secondary coenzyme Q10 deficiency results from mutations in genes that are not directly related to the CoQ10 biosynthetic pathway, or to non-genetic factors associated with various disorders—examples of the latter category include increased oxidative stress and the use of statin type pharmaceuticals, as summarised in Fig. 1. In this article, we have reviewed both common and less common sec-

ondary disorders in which a deficiency of CoQ10 has been identified, and highlighted those disorders in which CoQ10 supplementation has been shown to be of significant benefit; the article is specifically concerned with clinical studies, and pre-clinical studies in animal models of disease have in general not been reviewed.

2. CoQ10 Deficiency/Supplementation in Common Disorders

In this section of the article, we have reviewed organs/systems in which secondary deficiency of CoQ10 has been reported, including the heart, kidneys, liver and central nervous system (CNS).

2.1 Heart Failure

The most well-known example of a secondary CoQ10 deficiency disorder is heart failure. By definition, heart failure is a condition in which the heart is unable to maintain circulation of the blood sufficiently to supply the requirements of the body. Heart failure can be considered to be a condition of myocardial energy starvation, characterised by mitochondrial dysfunction, reduced ATP production, increased free radical generation/oxidative stress, and inflammation [4]. Depletion of both circulatory and cardiac tissue levels of CoQ10 have been reported. Plasma levels of CoQ10 in healthy subjects have been reported to be in the range of 0.8–1.2 µg/mL, with plasma levels in






Fig. 1. The potential factors responsible for a secondary CoQ10 deficiency. COQ10, Coenzyme Q10; OS, Oxidative stress; MRC, Mitochondrial respiratory chain.

heart failure patients being significantly lower; Molyneux *et al.* [4] reported an independent association between reduced plasma CoQ10 levels and increased risk of mortality in patients with chronic heart failure. The association with increased mortality risk was stronger for CoQ10 than for the N-terminal pro-brain natriuretic peptide (NT-proBNP); the study was unable to confirm an association between increased mortality risk and plasma cholesterol levels. With regards to CoQ10 deficiency in cardiac tissue, endomyocardial biopsies from heart failure patients showed significantly decreasing levels of CoQ10 with increasing severity of symptoms as follows: New York Heart Association (NYHA) class I, $0.40 \pm 0.06 \mu\text{g}/\text{mg}$ tissue dry weight; NYHA class II, $0.34 \pm 0.06 \mu\text{g}/\text{mg}$ tissue dry weight; NYHA Class III or IV individuals, $0.28 \pm 0.04 \mu\text{g}/\text{mg}$ tissue dry weight [5]. Supplementation with CoQ10 has been shown to restore both myocardial and circulatory CoQ10 to normal levels, with a concomitant improvement in clinical status. The best example of the beneficial effect of supplementary CoQ10 in heart failure is provided by the Q-SYMBIO randomised controlled clinical trial [6]. Patients with NYHA class III or IV heart failure were given supplementary CoQ10 ($3 \times 100 \text{ mg}/\text{day}$ for two years), in addition to conventional heart failure medication. Supplementation with CoQ10 significantly reduced the relative risk of both cardiac related deaths (43%) and all-cause mortality (42%). There was no significant difference in adverse events be-

tween the CoQ10-treated and placebo groups over the duration of the study. Sub-group analysis of the effect of CoQ10 supplementation in the European cohort (231 of 420 patients) of the Q-SYMBIO study has been reported [7]. In these patients, the relative risk of major adverse cardiovascular events (MACE) was reduced by 67%, cardiac-related mortality by 53% and all-cause mortality by 55%; in addition, left ventricular ejection fraction was significantly improved by 6%, which was not observed in the original study, although NT-proBNP levels were not significantly altered. The improved outcome in the European cohort probably results from better patient compliance (in taking the required supplementation) with supplementing CoQ10, resulting in a consistently higher plasma CoQ10 level for the duration of the study.

2.2 Chronic Kidney Disease

Plasma CoQ10 levels have been reported to be significantly lower in chronic kidney disease (CKD) patients (with or without haemodialysis), compared to healthy controls [8]. CoQ10 supplementation may improve renal function and reduce the need for dialysis in patients with CKD. In a randomised controlled study, 97 CKD patients were given supplementary CoQ10 ($3 \times 100 \text{ mg}$ daily for three months) or a placebo. There was a significant improvement in renal function (quantified via the marker of renal function, serum creatinine) in CoQ10-supplemented patients compared to the placebo, in both dialysed and non-dialysed patients. In particular, the number of patients requiring dialysis in the CoQ10-treated group decreased from 21 to 12, while remaining unchanged at 24 in the placebo group. Decreased CoQ10 levels may be a particular issue in CKD patients prescribed statins, since some studies have reported a deficit in CoQ10 status in association with this type of pharmacotherapy in a subset of patients [8].

2.3 Non-Alcoholic Fatty Liver Disease

With regard to liver disease, blood CoQ10 levels are reportedly depleted in non-alcoholic fatty liver disease (NAFLD) patients, with the decrease in CoQ10 status correlating with increased liver inflammation and cirrhosis [9]. Randomised controlled trials found that supplementation with CoQ10 ($100 \text{ mg}/\text{day}$ for 1–3 months) resulted in significantly decreased systemic levels of biochemical markers of liver damage, inflammation and oxidative stress (aspartate aminotransferase, gamma-glutamyl peptidase, C-reactive protein) as reviewed by Mantle & Hargreaves [9].

2.4 Type II Diabetes

Several studies have reported significantly reduced blood CoQ10 levels in type II diabetic patients, correlating with increased levels of plasma glucose, HbA1c and markers of oxidative stress. Kolahehdouz Mohammadi *et al.* [10] reported that CoQ10 supplementation ($200 \text{ mg}/\text{day}$ for three months) significantly reduced HbA1c levels in type II

diabetics. Similarly, Zahedi *et al.* [11] found that CoQ10 supplementation (150 mg/day for three months) significantly improved fasting plasma glucose and HbA1C levels, and Hosseinzadeh-Attar *et al.* [12] reported a significant improvement in HbA1c levels following supplementation with 200 mg/day for three months. The benefit of CoQ10 supplementation on glycaemic control and blood lipid levels has been confirmed in a recent meta-analysis by Zhang *et al.* [13].

2.5 Neurological Disorders

In Parkinson's disease (PD), a deficiency in cerebral CoQ10 status has been reported; a decrease in CoQ10 status has also been reported in both the plasma and platelets of PD patients [14]. In a phase II clinical trial conducted by Shults *et al.* [15], oral CoQ10 supplementation (300–1200 mg/day) was found to reduce the functional decline of patients with early-stage PD. A subsequent phase III clinical trial involving six hundred patients was undertaken with PD patients receiving CoQ10 dosages of 1200 or 2400 mg/d [16]. Despite 1200 mg/d being the highest dosage used in the previous study, the mean change in Unified Parkinson's Disease Rating Scale (UPDRS) score of treated patients was not found to be significantly lower than that of the placebo group; the researchers concluded that since CoQ10 appeared to show no apparent clinical benefit, they could not recommend its use in the treatment of early-stage PD. The contrasting findings of the clinical studies by Shults *et al.* [15] and Beal *et al.* [16] may reflect the broad range of sporadic PD patients used in the two clinical trials, with the heterogeneous patient populations contributing to their contradictory findings. Furthermore, no assessment of an underlying CoQ10 deficiency was determined in the PD patients prior to commencing CoQ10 supplementation in the study by Beal *et al.* [16], which may explain the limited therapeutic potential of CoQ10 reported. In multiple sclerosis, supplementation of patients with CoQ10 (500 mg/day for 3 months) reduced blood biomarkers of oxidative stress (malondialdehyde, total antioxidant capacity), reduced pro-inflammatory cytokine levels (IL-6, TNF alpha), and improved levels of fatigue [17–19].

2.6 Neuromuscular Disorders

Fibromyalgia patients have been shown to have depleted tissue levels (typically 40–50% of normal) of CoQ10, together with increased levels of mitochondrial dysfunction, oxidative stress and inflammation, both in adults and juveniles [20,21]. A randomised controlled clinical study by Cordero *et al.* [20] in 20 fibromyalgia patients found supplementation with CoQ10 (Pharma Nord Bio-Quinone, 300 mg/day for 40 days) significantly reduced (by more than 50%) pain and fatigue; there was a corresponding improvement in mitochondrial energy generation (via increased mitochondrial biogenesis), and reduced oxidative stress and inflammation. In this study, psychopathological symptoms (including depression) were also signif-

icantly improved; this was linked to the effect of supplemental CoQ10 in reducing oxidative stress and inflammation, as well as increased levels of serotonin [22,23]. In addition, Cordero *et al.* [24] correlated headache symptoms with reduced CoQ10 levels and increased oxidative stress in fibromyalgia patients, with headache symptoms and oxidative stress levels significantly improved following CoQ10 supplementation (300 mg/day for 3 months). Finally, in juvenile fibromyalgia patients, Miyamae *et al.* [21] reported coQ10 supplementation (100 mg/day for 3 months) significantly improved fatigue.

2.7 Sensory Disorders

A randomised controlled trial found supplementation with CoQ10, in combination with carnitine and omega-3 fatty acids, over a 12-month period improved visual function in patients with age related macular degeneration [25]. A randomised controlled trial of CoQ10, in combination with vitamin E (applied to the eye as an ophthalmic solution, CoQun® Visufarma SpA, Italy), in patients with open-angle glaucoma is currently in progress [26]. A randomised controlled trial in patients with dry eye syndrome found application of eye drops containing CoQ10 and hyaluronic acid daily for 3 months was effective in improving symptoms [27].

2.8 Pulmonary Disorders

The potential benefit of CoQ10 supplementation has been investigated in a number of pulmonary disorders, including chronic obstructive pulmonary disease (COPD), COVID, influenza and asthma. There is evidence for mitochondrial dysfunction, oxidative stress and inflammation in the pathogenesis of COPD, indicating a potential therapeutic role for supplementation with CoQ10 [28]. Blood levels of CoQ10 are reportedly decreased in COPD patients [29]. There have been two randomised controlled trials supplementing CoQ10 in COPD, using doses of 50 mg/day for 8 weeks [30] and 180 mg/day for 8 weeks [31] respectively; both showed a significant improvement in respiratory function (as assessed via spirometry) following CoQ10 supplementation. Mitochondrial dysfunction has been implicated in the mechanism of COVID-19 infection [32]. In patients with COVID-19, blood platelet mitochondrial function and CoQ10 levels were significantly reduced [33]. The potential role of supplemental CoQ10 in the management of COVID-19 patients has been reviewed by Hargreaves & Mantle [34]. In patients with influenza, blood CoQ10 levels are reportedly reduced in both seasonal and pandemic (H1N1) forms [35,36], although to date there have been no randomised controlled trials supplementing CoQ10 in influenza. Asthma is a disorder characterised by increased oxidative stress and inflammation of the airways. Blood levels of CoQ10 are reduced in asthma patients [37]. Supplementation with CoQ10 (100 mg/day for 4 weeks) improved airflow in asthmatic patients [38].

2.9 Cancer

Evidence of decreased plasma concentrations of CoQ10 has been reported in patients with cancer (breast cancer, myeloma, lymphoma, and lung cancer) [39,40]. Low plasma CoQ10 levels have been linked to an increased risk of breast cancer [41]. Joliet *et al.* [42] reported decreased levels of plasma CoQ10 in both patients with breast cancer, and also in patients with nonmalignant breast disease. These results indicated that the decreased CoQ10 levels may also be responsible for benign mammary cell growth. Clinical studies supplementing CoQ10 (390 mg/day for 3 years) in cancer patients were pioneered by Dr. Karl Folkers [43,44], in which improved patient survival was reported. Hertz & Lister [45] reported improved survival in patients with end stage cancers following supplementation with CoQ10 (300 mg/day for up to 9 years). To date there have been relatively few randomised controlled trials supplementing CoQ10 in cancer. Supplementation with CoQ10 (InnerPower® for 21 days) was reported to benefit fatigue in breast cancer patients by Iwase *et al.* [46], whilst Lesser *et al.* [47] reported no significant benefit. The anti-angiogenic action of CoQ10 (100 mg/day for 3 months, in combination with riboflavin and niacin) in breast cancer patients undergoing tamoxifen therapy has been described by Premkumar *et al.* [48]. Supplementary CoQ10 has been used to protect against anthracycline induced cardiotoxicity in patients with leukemia [49].

2.10 Reproductive Disorders

There have been several randomised controlled clinical trials relating to CoQ10 and semen parameters in male infertility. Supplementation with CoQ10 (200–300 mg/day for 12–26 weeks) resulted in significant improvements in sperm count, morphology and motility in infertile men [50–53]. Pre-treatment with CoQ10 (600 mg/day for 2 months) improved the ovarian response to stimulation and embryological parameters in young women with poor ovarian reserve in IVF-ICSI cycles [54].

2.11 Endocrine Disorders

CoQ10 levels in blood [55–57] and thyroid tissue [58] are reportedly reduced in hyperthyroid patients. Supplementation with CoQ10 (120 mg/day for 1 week) improved cardiac performance in hyperthyroid patients [59, 60]. Moncayo & Moncayo have described a therapeutic regime (60 mg/day ongoing) for the correction of CoQ10 deficiencies in patients with thyroid disease [61].

2.12 Gastrointestinal Disorders

In a randomised controlled clinical trial, supplementation with CoQ10 (200 mg/day for 8 weeks) significantly reduced levels of inflammatory markers and disease severity, and improved quality of life in patients with mild to moderate ulcerative colitis [62,63]. There are no studies listed on Medline relating to CoQ10 and Crohn's disease, celiac disease, irritable bowel syndrome or gastric reflux.

2.13 Arthritis

A randomised controlled trial by Nachvac *et al.* [64] found that supplementation of rheumatoid arthritis patients with CoQ10 (100 mg/day for 2 months) resulted in a reduction in matrix metalloproteinase activity (a contributor to joint damage), reduced joint swelling and pain score, and improved clinical outcome. A randomised controlled trial reported by Abdollahzad *et al.* [65] found supplementation of rheumatoid arthritis patients with CoQ10 (100 mg/day for 2 months) reduced blood levels of pro-inflammatory cytokines (IL-6 and TNF alpha) and the oxidative stress marker malondialdehyde.

2.14 Periodontal Disease

Periodontitis is a chronic condition in which degeneration of the supporting periodontal tissues (gingiva, periodontal ligaments, alveolar bone) ultimately results in tooth loss [66]. The initial cause of this condition is infection by various types of pathogenic Gram negative anaerobic bacteria, including *Fusobacterium*, *Bacteroides*, *Porphyromonas* and *Prevotella* species [67]. The formation of the resulting bacterial biofilm (plaque) on teeth initiates an immune response in the host, involving both the innate and adaptive immune systems [68]. Whilst some damage to the periodontal tissues results from the direct destructive action of these bacteria (via release of proteolytic enzymes), the majority of tissue damage results from over activation of the host immune system, resulting in a self-reinforcing cycle of inflammation, mitochondrial dysfunction and free radical induced oxidative stress [69]. CoQ10 is of potential relevance to periodontal disease, since it has potent antibacterial, antioxidant and anti-inflammatory action.

Several studies have provided evidence for a deficiency in coenzyme Q10 status in patients with periodontal disease. Thus a deficiency of CoQ10 in gingival biopsies of diseased tissue was identified, compared to biopsies taken from non-diseased areas in the same patients [70–72]. Similarly, Hansen *et al.* [73] found significant gingival and leukocytic deficiencies (typically 20%–60%) of coenzyme Q10 in patients with periodontal disease. In earlier supplementation studies, systemic or topical application of coenzyme Q10 in randomized placebo controlled clinical trials reported significant improvement in clinical status (e.g., pocket depth, gingival crevicular fluid flow, plaque scores) in patients with periodontal disease [74,75]. Despite these findings, the use of supplemental CoQ10 for the treatment of periodontal disease was questioned by Watts [76].

However, a number of more recent studies have provided evidence that topical application of CoQ10 (Perio Q10 gel® containing 10% CoQ10 in a vegetable oil base, 2 mL for 3 months) as an adjunct to scaling and root planing results in a significant improvement in periodontal disease status compared to scaling and root planing alone. In a randomised controlled trial comprising 40 patients who

were smokers, topical application of CoQ10 resulted in a significant improvement in plaque index, pocket probing depth, sulcular bleeding index and clinical attachment level over a 3-month period, compared to scaling and root planing alone [77]. It is of note that smokers often respond more poorly to conventional periodontal treatment, since cigarette smoke is itself a potent source of free radicals. Similarly, a study by Shaheen *et al.* [78] reported topical application of CoQ10 resulted in a significant improvement in periodontal parameters compared to scaling and root planing alone. In contrast, in a study of 16 patients with periodontitis, topical application of CoQ10 significantly increased crevicular antioxidant status (quantified as superoxide dismutase), but did not significantly affect periodontal parameters (pocket depth, plaque index, gingival index) compared to scaling and root planing alone [79].

3. CoQ10 Deficiency/Supplementation in Less Common Disorders

3.1 Multiple System Atrophy

Multiple system atrophy (MSA) is an example of one of the less common neurological disorders. MSA results from progressive degeneration of neurons and glia, with subsequent dysfunction of the autonomic nervous system. The pathogenesis of MSA has been linked to the dysfunction of an enzyme (COQ2; 4-parahydroxybenzoate: polyphenyl- transferase) in the CoQ10 synthetic pathway [80]. Several studies have reported a reduction in plasma or post-mortem brain tissue. Thus, in a series of 44 MSA patients, Mitsui *et al.* [81] found a significant reduction in the mean plasma CoQ10 level of approximately 30% compared to controls. Barca *et al.* [82] found CoQ10 levels to be significantly depleted (by 40%) in post-mortem cerebellar tissue from MSA patients, compared to controls. In addition, in a study using induced pluripotent stem cell (iPSC)-derived neurons, CoQ10 levels were significantly reduced in MSA patients, particularly those with COQ2 functional variants [83]. To date, there have been no randomised controlled trials of CoQ10 in MSA.

3.2 Progressive Supranuclear Palsy

Progressive supranuclear palsy (PSP) is a disorder resulting from tau protein aggregation in brain tissue, causing problems with balance, movement and vision. To date there have been two randomised controlled trials of supplementary CoQ10 in PSP. In the study by Stamelou *et al.* [84] of 20 PSP patients, supplementation with 5 mg/kg/day CoQ10 for 6 weeks resulted in improved cerebral energy metabolism assessed via magnetic resonance spectroscopy, as well as an improvement in PSP rating scale. In the study by Apetauerova *et al.* [85] of 60 PSP patients, supplementation with 2400 mg/day CoQ10 for up to 12 months did not significantly improve PSP symptoms or disease progression; however, the study had a high patient drop-out rate and lacked the precision to exclude a moderate benefit of CoQ10.

3.3 Ataxia

Hereditary ataxias (loss of coordination) can result from defects in a number of genes; these can be broadly divided into two types, resulting in primary or secondary CoQ10 deficiencies respectively. Cerebellar ataxia resulting from primary CoQ10 deficiency is a good example of a condition where CoQ10 administration can have a profound effect on clinical outcome, if supplementation is given at an early stage of disease. However, this article is concerned with secondary CoQ10 deficiencies, which in this case include Friedreich's ataxia (resulting from defective production of the protein frataxin), ataxia telangiectasia (resulting from a defective gene involved in DNA repair), spinocerebellar ataxia (SCA, resulting from defective production of the protein ataxin). There has been one randomised double blind, variable dose clinical trial to date supplementing CoQ10 in Friedreich's ataxia patients [86]; 50 patients were given either 600 mg CoQ10 and 2100 IU vitamin E daily, or 30 mg CoQ10 and 24 IU vitamin E daily, for a 2-year period. When compared to cross sectional data, approximately 50% of patients showed improved International Cooperative Ataxia Ratings Scale (ICARS) scores, with high and low dose treatments being equally effective. The study also identified responder and non-responder patient groups, with a low plasma CoQ10 level being the best predictor of positive clinical response to supplementation.

A clinical study of patients with SCA types 1, 2, 3 and 6 found previous administration of CoQ10 (mean 600 mg/day for 3 years) resulted in reduced Scale for Assessment and Rating of Ataxia (SARA) scores and improved clinical outcome in individuals with SCA 1 or SCA 3 [87]. In a study using cultured fibroblasts, Cornelius *et al.* [88] reported increased levels of oxidative stress and mitochondrial dysfunction in fibroblasts from SCA 2 patients, compared to controls; in addition, treatment with CoQ10 could partially reverse changes in these parameters in SCA 2 fibroblasts.

3.4 Lysosomal Storage Disorders

In lysosomes CoQ10 is thought to play an essential role in the transport of protons across the lysosomal membrane, which is required for maintaining the acidic pH (4.5–5) of the lumen of the organelle [89]. Proton translocation into the lumen is linked to the activity of a tentative respiratory chain (RC), where CoQ10 is believed to act as both an electron carrier and proton translocator [89]. The of the lumen is essential for the activity of lysosomal enzymes, such as those affected in San Filippo disease or mucopolysaccharidosis III (MPS III) [90]. MPS III is an autosomal recessive disorder caused by a mutation the genes encoding the enzymes required for the lysosomal degradation of heparin sulphate [91]. MPS III is characterized by childhood onset of speech delay, behavioural problems, progressive cognitive decline, loss of motor skills and epilepsy. A study by Delgadillo *et al.* [92] assessed the plasma CoQ10 level in 30

patients with a range of mucopolysaccharidosis disorders, including 19 with MPS III and found evidence of a CoQ10 deficiency in the majority of the MPS III patients. A subsequent study by Yubero *et al.* [93] which assessed the nutritional status of 9 of the original 19 patients from the former study confirmed evidence of a plasma CoQ10 deficiency in 8 out of the 9 patients, together with an associated loss of circulatory pyridoxal phosphate (PLP, the active form of vitamin B6). Importantly, PLP is required for initial transamination of tyrosine into 4-hydroxyphenylpyruvic acid in the CoQ10 biosynthetic pathway, and a study by Willis *et al.* [94] has indicated a strong correlation between blood CoQ10 and vitamin B6 levels. Therefore, the lowered circulatory level of PLP may have contributed to the plasma CoQ10 deficiency detected in the MPS III patients. Furthermore, the decreased circulatory levels of CoQ10 in MPS III patients may be associated with malabsorption of CoQ10 from the gut, due to increased submucosal thickening or diarrhea, both of which are commonly associated with MPS III. In view of the possible involvement of oxidative stress in the pathogenesis of MPS III, increased reactive oxygen species (ROS) induced consumption of CoQ10 may also be a contributory factor to the lowered circulatory levels of CoQ10 [95]. Decreased fibroblast CoQ10 status has also been reported in patients with MPS III, although cellular CoQ10 biosynthesis appeared to be unimpaired [96]. This latter result is supported by the normal levels of circulatory cholesterol reported in MPS III patients which indicates a functioning mevalonate pathway, a biosynthetic pathway shared by both CoQ10 and cholesterol, and therefore the deficit in CoQ10 status reported in this disorder may be an example of secondary CoQ10 deficiency. A recent study by Montero *et al.* [97] has reported evidence of plasma CoQ10 deficiency in a range of MPS patients including MPS III. The mechanism proposed to account for this diminution in circulatory CoQ10 levels was the possibility that heparan sulphate or mucopolysaccharides may create adducts with PLP, leading to a loss of vitamin B₆ and consequently low CoQ concentrations. Interestingly, CoQ10 treatment was found to increase the residual activity of the defective enzyme in MPS III patient fibroblasts indicating some possible therapeutic potential for CoQ10 in the treatment of this disorder [90].

Evidence of a CoQ10 deficiency has also been reported in the lysosomal storage disorder Niemann Pick disease Type C (NPC), which is a neurodegenerative disease characterised by impaired intracellular cholesterol and lipid trafficking [98]. The preponderance of cases of NPC are caused by mutations in the genes encoding for the transmembrane lysosomal proteins NPC1 and NPC2. Although the exact mechanisms of disease pathophysiology have yet to be elucidated, defective NPC1 and NPC2 proteins result in the accumulation of intracellular un-esterified cholesterol and glycosphingolipids in the liver, brain and spleen of patients [98]. Decreased CoQ10 status and biosyn-

thetic capacity has been reported in fibroblasts from patients with NPC. The aberrant CoQ10 synthetic capacity in this disorder has been suggested to result from the accumulation in cholesterol which may down regulate β -Hydroxy β -methylglutaryl-CoA (HMG-CoA) reductase activity, the rate limiting enzyme in CoQ10 biosynthesis, resulting in a decrease in CoQ10 biosynthesis [99]. A study by Fu *et al.* [100] assessed the serum CoQ10 status in 37 patients with NPC and found evidence of a CoQ10 deficiency in only 4 patients, suggesting that the deficit in CoQ10 status may not be a consistent finding in NPC. However, 22 of the 37 NPC patients were found to have decreased levels of serum total antioxidant capacity compared to the controls, indicating the possibility that oxidative stress may be a factor to consider in the pathophysiology of this disorder.

3.5 Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a genetic disorder of children, characterised by a variety of physical and neurological problems, in turn resulting from loss of function of genes on chromosome 15. There is some evidence that PWS is associated with mitochondrial dysfunction and reduced cellular energy metabolism [101]. Butler *et al.* [102] found plasma CoQ10 levels were significantly reduced in PWS patients compared to normal controls, but not when compared to obese controls. Miller *et al.* [103] found no significant difference in plasma CoQ10 levels between PWS patients and normal controls, although the authors questioned whether analysis of muscle biopsies, leucocytes or cultured fibroblasts may have been a more appropriate means of identifying abnormalities in CoQ10 metabolism. Eiholzer *et al.* [104] reported improved psychomotor development following supplementation with CoQ10 (2.5 mg/kg/day for 12 months). CoQ10 supplementation has been widely used in the management of PWS patients; of particular note is the work of Dr. William Judy of the SIBR research organisation (see <http://www.cytomed.net>), who has supplemented CoQ10 in more than 100 children with Prader-Willi syndrome over the course of more than 20 years. A randomised controlled cross-over clinical trial to determine the potential benefit of CoQ10 supplementation in PWS patients is currently in progress led by Dr. Ingrid Tein, Hospital for Sick Children, Toronto, Canada.

3.6 Leigh's Syndrome

Leigh's syndrome is a neurodegenerative disorder manifesting in early childhood, resulting in genetic defects affecting the process of oxidative phosphorylation; these can include dysfunction in the metabolism of pyruvate dehydrogenase or coenzyme Q10. Chen *et al.* [105] described the successful treatment of a child with Leigh's syndrome resulting from the m.10197 G>A mutation. Martinelli *et al.* [106], Enns *et al.* [107] and Kouga *et al.* [108] described improvements in a Leigh's syndrome patients following treatment with EPI 743 (100 mg/day for 12 weeks),

an analogue of CoQ10. Haginoya *et al.* [109] reported improved respiratory function in a Leigh's syndrome patient following supplementation with the CoQ10 analogue, idebenone [110].

3.7 Kearns-Sayre Syndrome

Kearns-Sayre syndrome is a neuromuscular disorder resulting from mitochondrial DNA deletions; the disorder is associated with characteristic visual problems, including ptosis and corneal lesions. In a cohort of 5 Kearns-Sayre patients, CoQ10 supplementation (150 mg/day) improved abnormal metabolism of pyruvate and NADH oxidation in skeletal muscle; ECG abnormalities and neurologic symptoms also improved [111]. There have been several case studies of individual Kearns-Sayre patients whose symptoms (lactate/pyruvate metabolism, ocular movement, cardiac function) improved following supplementation (150 mg/day for up to 3 years) with CoQ10 [112]. Kim *et al.* [113] described improvements in corneal disease in two children with Kearns-Sayre syndrome following supplementation with CoQ10.

3.8 Down Syndrome

Down syndrome is a genetic development disorder resulting from the presence of an extra chromosome 21. There is evidence for involvement of mitochondrial dysfunction, oxidative stress and inflammation in the pathogenesis of Down syndrome; several clinical studies have demonstrated improved levels of oxidative stress/inflammation in DMD patients following supplementation with CoQ10 (10 mg/kg/day for 3 months) [114–116].

3.9 Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder (resulting in the absence of dystrophin protein) manifesting in male children, characterised by progressive wasting of skeletal muscles, with death in the late teens/early twenties following involvement of the respiratory and cardiac musculature. The blood levels of CoQ10 were significantly reduced in DMD patients, in common with other forms of muscular dystrophy [117]. Several randomised controlled clinical studies have reported a significant improvement in respiratory function in DMD patients following supplementation (900 mg/day for up to 6 years) with idebenone [118].

4. Discussion

As noted in the introduction to this article, secondary CoQ10 deficiencies can result from a variety of causes, which typically may reduce CoQ10 synthesis or increase its catabolism, as summarized in Fig. 1. In view of the central role of CoQ10 in cellular metabolism, it is unsurprising that a deficiency in endogenous CoQ10 status may be associated with a wide range of clinical presentations. In the present article we have identified a wide range of such disorders,

both common and uncommon, in which secondary CoQ10 deficiencies have been reported. Whether such CoQ10 deficiencies occur as a cause or consequence of these disorders has still to be fully elucidated. However, notwithstanding cause or consequence, the important issue is whether supplementation with CoQ10 can result in significant symptomatic benefit; this is particularly the case for those disorders for which conventional therapies are ineffective, or not available at all. We have therefore reviewed a similar range of disorders in which secondary CoQ10 deficiency has been corrected following oral CoQ10 supplementation, resulting in a significant improvement in clinical status, as validated in randomised controlled clinical trials.

The best documented secondary CoQ10 deficiency disorder in which CoQ10 supplementation has been shown to provide significant patient benefit is heart failure. There have been some 30 randomised controlled trials supplementing CoQ10 in heart failure, almost all of which have reported significant patient benefit [119]. The efficacy and safety of supplemental CoQ10 for treatment of heart failure have been confirmed by meta-analysis [120,121]. Heart failure may develop as a complication of other disorders; patients with type II diabetes, non-alcoholic fatty liver disease (NAFLD) and CKD are at increased risk of developing heart failure. Supplementation with CoQ10 in patients with these disorders may therefore help to prevent heart failure; in addition, there is evidence from randomised controlled trials that supplementary CoQ10 can improve blood glucose control, liver and renal function in these disorders respectively, as noted in the relevant sections of this article.

Supplementation with CoQ10 has not been universally successful in all secondary CoQ10 deficiency disorders; the lack of benefit in some randomised controlled trials may result from a number of factors, including bioavailability, dosage of CoQ10, duration of therapy, patient selection, and unknown factors in CoQ10 metabolism may influence the efficiency of this treatment.

Supplemented CoQ10 is absorbed in the small intestine where it is fully reduced into its ubiquinol form in enterocytes before entry into the lymphatic system and release into the circulation [122]. Bioavailability is a particular problem; the bioavailability of CoQ10 is low, typically of the order of 5% at best [122]. Bioavailability is highly dependent on supplement formulation, in particular the degree of CoQ10 crystal dispersion as demonstrated in the study by Lopez-Lluch *et al.* [123]. Despite its limitations, there is presently no alternative method of administering CoQ10; whilst intravenous administration of CoQ10 has been described in animal models of disease, there have been no randomised controlled trials using this administration method to date. Supplementation of CoQ10 in neurological disorders such as PD has been particularly disappointing; this in turn may result from a lack of knowledge of some aspects of CoQ10 metabolism, for example whether CoQ10 can cross the blood-brain barrier in man, and how CoQ10 is subse-

quently transported between and within brain cells [14]. For some of the less common disorders described in this review, current treatments may lack efficacy, so patient benefit following CoQ10 supplementation is of potential importance, and worthy of further clinical investigations. Furthermore, at present there is no consensus on dosage or circulatory level of CoQ10 which may be of therapeutic value in the treatment of disease.

The assessment of CoQ10 status is well established in specialist laboratories [124]. In general, clinical assessment is based on serum/plasma determinations, with an established reference interval ranging from 0.5 to 1.7 uM. The actual reference range can vary between laboratories depending on the precise method of analysis employed. Generally, high performance liquid chromatography (HPLC) with either ultra violet (UV; at 275 nm) or electrochemical detection is used, although mass spectrographic (M) analysis is becoming more readily accessible. On the basis of the data provided in this review, we suggest that the measurement of endogenous CoQ10 status should become more of a routine assay in hospital clinical biochemistry laboratories, and that supplemental CoQ10 should be more widely utilised in clinical practice than is currently the case.

Abbreviations

COQ10, coenzyme Q10; OS, oxidative stress; MRC, mitochondrial respiratory chain.

Author Contributions

DM, NT and IPH wrote the manuscript and prepared the figure. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

Mantle is medical adviser to Pharma Nord (UK) Ltd. Iain P. Hargreaves is serving as Guest Editor of this journal. We declare that Iain P. Hargreaves had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Graham Pawelec.

References

- [1] Crane FL. Biochemical functions of coenzyme Q10. *Journal of the American College of Nutrition*. 2001; 20: 591–598.

- [2] Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10 and immune function: an overview. *Antioxidants*. 2021; 10: 759.
- [3] Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme Q10 metabolism: An overview. *International Journal of Molecular Sciences*. 2020; 21: 6695.
- [4] Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, *et al.* Coenzyme Q10: an independent predictor of mortality in chronic heart failure. *Journal of the American College of Cardiology*. 2008; 52: 1435–1441.
- [5] Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. *Proceedings of the National Academy of Sciences of the United States of America*. 1985; 82: 901–904.
- [6] Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, *et al.* The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. *JACC: Heart Failure*. 2014; 2: 641–649.
- [7] Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. *Cardiology Journal*. 2019; 26: 147–156.
- [8] Hargreaves I, Mantle D, Milford D. Chronic kidney disease and coenzyme Q10 supplementation. *Journal of Kidney Care*. 2019; 4: 82–90.
- [9] Mantle D, Hargreaves IP. Coenzyme Q10 supplementation in non-alcoholic fatty liver disease: an overview. *Gastrointestinal Nursing*. 2020; 18: 200–204.
- [10] Kolahdouz Mohammadi R, Hosseinzadeh-Attar MJ, Eshraghian MR, Nakhjavani M, Khorami E, Esteghamati A. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. *Minerva Gastroenterologica e Dietologica*. 2013; 59: 231–236.
- [11] Zahedi H, Egtesadi S, Seifirad S, Rezaee N, Shidfar F, Heydari I, *et al.* Effects of CoQ10 supplementation on lipid profiles and glycemic control in patients with Type 2 diabetes: a randomized, double blind, placebo-controlled trial. *Journal of Diabetes & Metabolic Disorders*. 2014; 13: 81.
- [12] Hosseinzadeh-Attar M, Kolahdouz Mohammadi R, Eshraghian M, Nakhjavani M, Khorami E, Ebadi M, *et al.* Reduction in asymmetric dimethylarginine plasma levels by coenzyme Q10 supplementation in patients with type 2 diabetes mellitus. *Minerva Endocrinologica*. 2015; 40: 259–266.
- [13] Zhang SY, Yang KL, Zeng LT, Wu XH, Huang HY. Effectiveness of coenzyme Q10 supplementation for Type 2 diabetes mellitus: A systematic review and meta-analysis. *International Journal of Endocrinology*. 2018; 40: 259–266.
- [14] Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10, ageing and the nervous system: an overview. *Antioxidants*. 2021; 11: 1–12.
- [15] Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, *et al.* Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Archives of Neurology*. 2002; 59: 1541–1550.
- [16] Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, *et al.* A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurology*. 2014; 71: 543–552.
- [17] Sanoobar M, Egtesadi S, Azimi A, Khalili M, Jazayeri S, Reza Gohari M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing–remitting multiple sclerosis. *International Journal of Neuroscience*. 2013; 123: 776–782.
- [18] Sanoobar M, Egtesadi S, Azimi A, Khalili M, Khodadadi B,

- Jazayeri S, *et al.* Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. *Nutritional Neuroscience*. 2015; 18: 169–176.
- [19] Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Jazayeri S, Reza Gohari M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing–remitting multiple sclerosis. *International Journal of Neuroscience*. 2013; 123: 776–782.
- [20] Cordero MD, Alcocer-Gómez E, de Miguel M, Culic O, Carrión AM, Alvarez-Suarez JM, *et al.* Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? *Antioxidants & Redox Signaling*. 2013; 19: 1356–1361.
- [21] Miyamae T, Seki M, Naga T, Uchino S, Asazuma H, Yoshida T, *et al.* Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. *Redox Report*. 2013; 18: 12–19.
- [22] Alcocer-Gómez E, Sánchez-Alcázar JA, Cordero MD. Coenzyme q10 regulates serotonin levels and depressive symptoms in fibromyalgia patients: results of a small clinical trial. *Journal of Clinical Psychopharmacology*. 2014; 34: 277–278.
- [23] Alcocer-Gómez E, Culic O, Navarro-Pando JM, Sánchez-Alcázar JA, Bullón P. Effect of Coenzyme Q10 on psychopathological symptoms in fibromyalgia patients. *CNS Neuroscience & Therapeutics*. 2017; 23: 188–189.
- [24] Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. *PLoS ONE*. 2012; 7: e35677.
- [25] Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. *Ophthalmologica*. 2005; 219: 154–166.
- [26] Quaranta L, Riva I, Biagioli E, Rulli E, Rulli E, Poli D, *et al.* Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: a Study Protocol. *Advances in Therapy*. 2019; 36: 2506–2514.
- [27] Postorino EI, Rania L, Aragona E, Mannucci C, Alibrandi A, Calapai G, *et al.* Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. *European Journal of Ophthalmology*. 2018; 28: 25–31.
- [28] Zozina VI, Covantev S, Kukes VG, Corlateanu A. Coenzyme Q10 in COPD: An Unexplored Opportunity? *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2021; 18: 114–122.
- [29] Tanrikulu AC, Abakay A, Evliyaoglu O, Palanci Y. Coenzyme Q10, copper, zinc, and lipid peroxidation levels in serum of patients with chronic obstructive pulmonary disease. *Biological Trace Element Research*. 2011; 143: 659–667.
- [30] Satta A, Grandi M, Landoni CV, Migliori GB, Spanevello A, Vocaturo G, *et al.* Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. *Clinical therapeutics*. 1991; 13: 754–757.
- [31] De Benedetto F, Pastorelli R, Ferrario M, de Blasio F, Marinari S, Brunelli L, *et al.* Supplementation with Qter ® and Creatine improves functional performance in COPD patients on long term oxygen therapy. *Respiratory medicine*. 2018; 142: 86–93.
- [32] Gvozdjakova A, Klaufu F, Kucharska J, Sumbalova Z. Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19? *Bratislava Medical Journal*. 2020; 121: 775–778.
- [33] Sumbalova Z, Kucharska J, Palacka P, Rausova Z, Langsjoen PH, Langsjoen AM, *et al.* Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients after COVID-19. *Bratislavske Lekarske Listy*. 2021; 123: 9–15.
- [34] Hargreaves IR, Mantle D. COVID-19, Coenzyme Q10 and Selenium. Identification of Biomarkers, New Treatments, and Vaccines for COVID-19. 2021; 13: 161–168.
- [35] Kelekçi S, Evliyaoglu O, Sen V, Yolbaş I, Uluca U, Tan I, Gürkan MF. The relationships between clinical outcome and the levels of total antioxidant capacity (TAC) and coenzyme Q (CoQ 10) in children with pandemic influenza (H 1 N1) and seasonal flu. *European Review for Medical and Pharmacological Sciences*. 2012; 16: 1033–1038.
- [36] Chase M, Cocchi MN, Liu X, Andersen LW, Holmberg MJ, Donnino MW. Coenzyme Q10 in acute influenza. *Influenza and other Respiratory Viruses*. 2019; 13: 64–70.
- [37] Gazdik F, Gvozdjaková A, Nádvorníková R, Repická L, Jahnová E, Kucharská J, *et al.* Decreased levels of coenzyme Q(10) in patients with bronchial asthma. *Allergy*. 2002; 57: 811–814.
- [38] Comhair SA, Grandon D, Khan A, Zhang R, Hazen SL, Erzurum SC. Coenzyme Q10 in asthma. *American Journal of Respiratory and Critical Care Medicine*. 2015; 191: 1336–1338.
- [39] Folkers K. Relevance of the Biosynthesis of Coenzyme Q10 and of the Four Bases of DNA as a Rationale for the Molecular Causes of Cancer and a Therapy. *Biochemical and Biophysical Research Communications*. 1996; 224: 358–361.
- [40] Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. *Biochemical and Biophysical Research Communications*. 1997; 234: 296–299.
- [41] Cooney RV, Dai Q, Gao Y, Chow W, Franke AA, Shu X, *et al.* Low Plasma Coenzyme Q10 Levels and Breast Cancer Risk in Chinese Women. *Cancer Epidemiology, Biomarkers and Prevention*. 2011; 20: 1124–1130.
- [42] Jolliet P, Simon N, Barré J, Pons JY, Boukef M, Paniel BJ, *et al.* Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. *International Journal of Clinical Pharmacology and Therapeutics*. 1998; 36: 506–509.
- [43] Folkers K, Brown R, Judy WV, Morita M. Survival of Cancer Patients on Therapy with Coenzyme Q10. *Biochemical and Biophysical Research Communications*. 1993; 192: 241–245.
- [44] Lockwood K, Moesgaard S, Folkers K. Partial and Complete Regression of Breast Cancer in Patients in Relation to Dosage of Coenzyme Q10. *Biochemical and Biophysical Research Communications*. 1994; 199: 1504–1508.
- [45] Hertz N, Lister RE. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. *Journal of International Medical Research*. 2009; 37: 1961–1971.
- [46] Iwase S, Kawaguchi T, Yotsumoto D, Doi T, Miyara K, Odagiri H, *et al.* Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). *Supportive Care in Cancer*. 2016; 24: 637–646.
- [47] Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, *et al.* A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer. *The Journal of Supportive Oncology*. 2013; 11: 31–42.
- [48] Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. *Vascular Pharmacology*. 2008; 48: 191–201.
- [49] Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, *et al.* Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Molecular Aspects of Medicine*. 1994; 15: s207–s212.

- [50] Safarinejad MR. Efficacy of Coenzyme Q10 on Semen Parameters, Sperm Function and Reproductive Hormones in Infertile Men. *Journal of Urology*. 2009; 182: 237–248.
- [51] Balercia G, Buldregini E, Vignini A, Tiano L, Paggi F, Amoroso S, *et al.* Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. *Fertility and Sterility*. 2009; 91: 1785–1792.
- [52] Cheng JB, Zhu J, Ni F, Jiang H. L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial. *National Journal of Andrology*. 2018; 24: 33–38.
- [53] Alahmar AT, Sengupta P. Impact of Coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. *Biological Trace Element Research*. 2021; 199: 1246–1252.
- [54] Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, *et al.* Pre-treatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. *Reproductive Biology and Endocrinology*. 2018; 16: 29.
- [55] Ogura F, Morii H, Ohno M, Ueno T, Kitabatake S, Hamada N, *et al.* Serum coenzyme Q10 levels in thyroid disorders. *Hormone and Metabolic Research*. 1980; 12: 537–540.
- [56] Pandolfi C, Ferrari D, Stanic I, Pellegrini L. Circulating levels of CoQ10 in hypo- and hyperthyroidism. *Minerva Endocrinologica*. 1994; 19: 139–142.
- [57] Bianchi G, Solaroli E, Zaccheroni V, Grossi G, Bargossi AM, Melchionda N, *et al.* Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment. *Hormone and Metabolic Research*. 1999; 31: 620–624.
- [58] Mano T, Iwase K, Hayashi R, Hayakawa N, Uchimura K, Makino M, *et al.* Vitamin E and Coenzyme Q Concentrations in the Thyroid Tissues of Patients with Various Thyroid Disorders. *The American Journal of the Medical Sciences*. 1998; 315: 230–232.
- [59] Suzuki H, Naitoh T, Kuniyoshi S, Banba N, Kuroda H, Suzuki Y, *et al.* Cardiac performance and coenzyme Q10 in thyroid disorders. *Endocrinologia Japonica*. 1984; 31: 755–761.
- [60] Naito T. Abnormal cardiac index measured by means of systolic time intervals and the effect of co-enzyme Q10 in thyroid disorders. *Nihon Naibunpi Gakkai Zasshi*. 1986; 62: 619–630.
- [61] Moncayo R, Moncayo H. Practical Guidelines for Diagnosing and Treating Thyroid Disease Based on the WOMED Metabolic Model of Disease Focusing on Glycolysis and Coenzyme Q 10 Deficiency-A Clinical Alternative to the 2021 Retired Clinical Practice Guidelines of the Endocrine Society. *Diagnostics*. 2022; 12: 107.
- [62] Farsi F, Ebrahimi-Daryani N, Golab F, Akbari A, Janani L, Karimi MY, *et al.* A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis. *European Journal of Nutrition*. 2021; 60: 3397–3410.
- [63] Farsi F, Ebrahimi-Daryani N, Barati M, Janani L, Karimi MY, Akbari A, *et al.* Effects of coenzyme Q10 on health-related quality of life, clinical disease activity and blood pressure in patients with mild to moderate ulcerative colitis: a randomized clinical trial. *Medical Journal of the Islamic Republic of Iran*. 2021; 35: 3.
- [64] Nachvak SM, Alipour B, Mahdavi AM, Aghdashi MA, Abdollahzad H, Pasdar Y, *et al.* Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. *Clinical Rheumatology*. 2019; 38: 3367–3374.
- [65] Abdollahzad H, Aghdashi MA, Asghari Jafarabadi M, Alipour B. Effects of Coenzyme Q10 Supplementation on Inflammatory Cytokines (TNF- α , IL-6) and Oxidative Stress in Rheumatoid Arthritis Patients: a Randomized Controlled Trial. *Archives of Medical Research*. 2015; 46: 527–533.
- [66] Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nature Reviews Disease Primers*. 2017; 3: 17038.
- [67] Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL. Microbial complexes in subgingival plaque. *Journal of Clinical Periodontology*. 1998; 25: 134–144.
- [68] Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. *Periodontology 2000*. 2014; 64: 57–80.
- [69] Sczepanik FSC, Grossi ML, Casati M, Goldberg M, Glogauer M, Fine N, *et al.* Periodontitis is an inflammatory disease of oxidative stress: we should treat it that way. *Periodontology*. 2020; 84: 45–68.
- [70] Littarru GP, Nakamura R, Ho L, Folkers K, Kuzell WC. Deficiency of coenzyme Q 10 in gingival tissue from patients with periodontal disease. *Proceedings of the National Academy of Sciences of the United States of America*. 1971; 68: 2332–2335.
- [71] Nakamura R, Littarru GP, Folkers K, Wilkinson EG. Deficiency of CoQ10 in gingiva of patients with periodontal disease. *Proceedings of the National Academy of Sciences of the United States of America*. 1973; 43: 84–92.
- [72] Nakamura R, Littarru GP, Folkers K, Wilkinson EG. Study of CoQ10 enzymes in gingiva from patients with periodontal disease and evidence for a deficiency of CoQ10. *Proceedings of the National Academy of Sciences of the United States of America*. 1974; 71: 1456–1460.
- [73] Hansen II, Iwamoto Y, Kishi T, Folkers K, Thompson LE. Energetics in clinical medicine: gingival and leucocytic deficiencies of COQ10 in patients with periodontal disease. *Research Communications in Chemical Pathology and Pharmacology*. 1976; 14: 729–738.
- [74] Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. adjunctive treatment of periodontal disease with coenzyme Q10. *Research Communications in Chemical Pathology and Pharmacology*. 1976; 14: 715–719.
- [75] Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of CoQ10 on adult periodontitis. *Molecular Aspects of Medicine*. 1994; 15: 241–248.
- [76] Watts TL. Coenzyme Q10 and periodontal treatment: is there any potential benefit? *British Dental Journal*. 1995; 178: 209–213.
- [77] Raut CP, Sethi KS, Kohale B, Mamajiwal A, Warang A. Sub-lingually delivered coenzyme Q10 in the treatment of chronic periodontitis among smokers: a randomized, controlled clinical study. *Journal of Oral Biology and Craniofacial Research*. 2019; 9: 204–208.
- [78] Shaheen MA, Elmeadawy SH, Bazeed FB, Anees MM, Saleh NM. Innovative CoQ10 loaded nanoformulation as an adjunct approach to the management of moderate periodontitis. *Drug Delivery and Translational Research*. 2020; 10: 548–564.
- [79] Pranam S, Palwankar P, Pandey R, Goyal A. Evaluation of Efficacy of Coenzyme Q10 as an Adjunct to Nonsurgical Periodontal Therapy and its Effect on Crevicular Superoxide Dismutase in Patients with Chronic Periodontitis. *European Journal of Dentistry*. 2020; 14: 551–557.
- [80] Mantle D, Turton N, Hargreaves IP. Multiple system atrophy: role of coenzyme Q10. *Journal of Clinical and Medical Research*. 2022; 4: 1–7.
- [81] Mitsui J, Matsukawa T, Yasuda T, Ishiura H, Tsuji S. Plasma Coenzyme Q10 levels in patients with Multiple System Atrophy. *JAMA neurology*. 2016; 73: 977–980.

- [82] Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, *et al.* Decreased Coenzyme Q10 levels in Multiple System Atrophy cerebellum. *Journal of Neuropathology & Experimental Neurology*. 2016; 75: 663–672.
- [83] Nakamoto FK, Okamoto S, Mitsui J, Sone T, Ishikawa M, Yamamoto Y, *et al.* The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. *Scientific Reports*. 2018; 8: 14215.
- [84] Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, *et al.* Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. *Movement Disorders*. 2008; 23: 942–949.
- [85] Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, *et al.* CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. *Neurology - Neuroimmunology Neuroinflammation*. 2016; 3: e266.
- [86] Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. *European Journal of Neurology*. 2008; 15: 1371–1379.
- [87] Lo RY, Figueroa KP, Pulst SM, Lin C, Perlman S, Wilmot G, *et al.* Coenzyme Q10 and spinocerebellar ataxias. *Movement Disorders*. 2015; 30: 214–220.
- [88] Cornelius N, Wardman JH, Hargreaves IP, Neergeen V, Bie AS, Tümer Z, *et al.* Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: Effect of coenzyme Q10 supplementation on these parameters. *Mitochondrion*. 2017; 34: 103–114.
- [89] Gille L, Nohl H. The Existence of a Lysosomal Redox Chain and the Role of Ubiquinone. *Archives of Biochemistry and Biophysics*. 2000; 375: 347–354.
- [90] Matalonga L, Arias A, Coll MJ, Garcia-Villoria J, Gort L, Ribes A. Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. *Journal of Inherited Metabolic Disease*. 2014; 37: 439–446.
- [91] Neufeld EF. Enzyme replacement therapy – a brief history. In: Mehta A, Beck M, Sunder-Plassmann G (eds.) *Fabry Disease: Perspectives from 5 Years of FOS*. Oxford PharmaGenesis: Oxford. 2006.
- [92] Delgadillo V, O'Callaghan MDM, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. *Journal of Inherited Metabolic Disease*. 2011; 34: 1039–1044.
- [93] Yubero D, Montero R, O'Callaghan M, Pineda M, Meavilla S, Delgadillo V, *et al.* Coenzyme Q 10 and Pyridoxal Phosphate Deficiency Is a Common Feature in Mucopolysaccharidosis Type III. *JIMD Reports*, Volume 25 (pp. 1–7). Springer: Berlin, Heidelberg. 2015.
- [94] Willis R, Anthony M, Sun L, Honse Y, Qiao G. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. *Biofactors*. 1999; 9: 359–363.
- [95] Cocco T, Pacelli C, Sgobbo P, Villani G. Control of OXPHOS efficiency by complex i in brain mitochondria. *Neurobiology of Aging*. 2009; 30: 622–629.
- [96] Buján N, Arias A, Montero R, García-Villoria J, Lissens W, Seneca S, *et al.* Characterization of CoQ10 biosynthesis in fibroblasts of patients with primary and secondary CoQ10 deficiency. *Journal of Inherited Metabolic Disease*. 2014; 37: 53–62.
- [97] Montero R, Yubero D, Salgado MC, González MJ, Campistol J, O'Callaghan MDM, *et al.* Plasma coenzyme Q10 status is impaired in selected genetic conditions. *Scientific Reports*. 2019; 9: 793.
- [98] Vanier MT, Caillaud C. Disorders of Sphingolipid Metabolism and Neuronal Ceroid-Lipofuscinoses. In: Saudubray J, van den Berghe G, Walter JH (eds.) *Inborn Metabolic Diseases; Diagnosis and Treatment* (pp. 569–571). 5th edn. Springer: Verlag Berlin Heidelberg. 2012.
- [99] Yubero D, Montero R, Martín MA, Montoya J, Ribes A, Grazina M, *et al.* Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. *Mitochondrion*. 2016; 30: 51–58.
- [100] Fu R, Yanjanin NM, Bianconi S, Pavan WJ, Porter FD. Oxidative stress in Niemann-Pick disease, type C. *Molecular Genetics and Metabolism*. 2010; 101: 214–218.
- [101] Butler MG, Hossain WA, Tessman R, Krishnamurthy PC. Preliminary observations of mitochondrial dysfunction in Prader-Willi syndrome. *American Journal of Medical Genetics Part A*. 2018; 176: 2587–2594.
- [102] Butler MG, Dasouki M, Bittel D, Hunter S, Naini A, DiMauro S. Coenzyme Q10 levels in Prader-Willi syndrome: Comparison with obese and non-obese subjects. *American Journal of Medical Genetics*. 2003; 119A: 168–171.
- [103] Miller JL, Lynn CH, Shuster J, Driscoll DJ. Carnitine and coenzyme Q10 levels in individuals with Prader-Willi syndrome. *American Journal of Medical Genetics Part A*. 2011; 155: 569–573.
- [104] Eiholzer U, Meinhardt U, Rousson V, Petrovic N, Schlumpf M, l'Allemand D. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. *American Journal of Medical Genetics Part A*. 2008; 146A: 873–880.
- [105] Chen Z, Zhao Z, Ye Q, Chen Y, Pan X, Sun B, *et al.* Mild clinical manifestation and unusual recovery upon coenzyme Q10 treatment in the first Chinese Leigh syndrome pedigree with mutation m.10197 G>A. *Molecular Medicine Reports*. 2015; 11: 1956–1962.
- [106] Martinelli D, Catteruccia M, Piemonte F, Pastore A, Tozzi G, Dionisi-Vici C, *et al.* EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined Leigh Syndrome. *Molecular Genetics and Metabolism*. 2012; 107: 383–388.
- [107] Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, *et al.* Initial experience in the treatment of inherited mitochondrial disease with EPI-743. *Molecular Genetics and Metabolism*. 2012; 105: 91–102.
- [108] Kouga T, Takagi M, Miyauchi A, Shimbo H, Iai M, Yamashita S, *et al.* Japanese Leigh syndrome case treated with EPI-743. *Brain and Development*. 2018; 40: 145–149.
- [109] Haginoya K, Miyabayashi S, Kikuchi M, Kojima A, Yamamoto K, Omura K, *et al.* Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. *Journal of the Neurological Sciences*. 2009; 278: 112–114.
- [110] Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. *Expert Opinion on Drug Metabolism & Toxicology*. 2010; 6: 1437–1444.
- [111] Ogasahara S, Nishikawa Y, Yorifuji S, Soga F, Nakamura Y, Takahashi M, *et al.* Treatment of Kearns-Sayre syndrome with coenzyme Q10. *Neurology*. 1986; 36: 45–53.
- [112] Calatayud MT, Díaz-Castroverde AG, Solar M, Díaz M, Uriá DF, Martínez C, *et al.* Treatment with ubiquinone in Kearns-Sayre syndrome. Improvement in ocular motility and visual evoked potentials. *Neurologia*. 1992; 7: 266–269.
- [113] Kim J, Medsing A, Chauhan B, Wiest C, Scanga H, Monaghan R, *et al.* Coenzyme Q10 in the Treatment of Corneal Edema in Kearns-Sayre: Is There an Application in Fuchs Endothelial Corneal Dystrophy? *Cornea*. 2016; 35: 1250–1254.
- [114] Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, *et al.* Coenzyme Q10 (Ubiquinol-10) Supplementation Improves Oxidative Imbalance in Children with Trisomy 21. *Pediatric Neurology*. 2007; 37: 398–403.
- [115] Tiano L, Padella L, Santoro L, Carnevali P, Principi F, Bruguè F,

- et al.* Prolonged coenzyme Q10 treatment in down syndrome patients, effect on DNA oxidation. *Neurobiology of Aging*. 2012; 33: 626.e1–626.e8.
- [116] Zaki ME, El-Bassyouni HT, Tosson AM, Youness E, Hussein J. Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects. *Jornal de Pediatria*. 2017; 93: 100–104.
- [117] Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. *Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease*. 1995; 1271: 281–286.
- [118] Servais L, Straathof CSM, Schara U, Klein A, Leinonen M, Hasham S, *et al.* Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. *Neuromuscular Disorders*. 2020; 30: 5–16.
- [119] Mantle D. Coenzyme Q10 and cardiovascular disease: an overview. *British Journal of Cardiology*. 2015; 22: 160.
- [120] Claxton L, Simmonds M, Beresford L, Cubbon R, Dayer M, Gottlieb SS, *et al.* Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. *Health Technology Assessment*. 2022; 26: 1–128.
- [121] Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. *BMC Cardiovascular Disorders*. 2017; 17: 196.
- [122] Mantle D, Dybring A. Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism. *Antioxidants*. 2020; 9: 386.
- [123] López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, Cortés-Rodríguez AB, Navas P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. *Nutrition*. 2019; 57: 133–140.
- [124] Yubero D, Montero R, Artuch R, Land JM, Heales SJ, *et al.* Biochemical diagnosis of coenzyme q10 deficiency. *Molecular Syndromology*. 2014; 5: 147–155.